Fig. 4: NSLC01 inhibited tumor growths of NRF2-activated PDAC PDX models in vivo. | Cell Death & Disease

Fig. 4: NSLC01 inhibited tumor growths of NRF2-activated PDAC PDX models in vivo.

From: Compound NSC84167 selectively targets NRF2-activated pancreatic cancer by inhibiting asparagine synthesis pathway

Fig. 4

A Tumor growth of PATX102 (resistant), PATX110 (sensitive), and PATX124 (sensitive). PDXs models were established in nude mice, and when tumors reached the sizes of ~100 mm3, mice (5–8 mice per group) were treated with vehicle control or NSCL01 (50 mg/kg) for 6 weeks. B Gross tumors from control and NSCL01-treated groups. C Immunohistochemistry staining of cleaved caspase-3 in tumor specimens after treatment. D Quantitation of cleaved capase-3 in immunohistochemistry analysis. **P < 0.01.

Back to article page